Compare HRTG & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | CAPR |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 670.9M | 584.9M |
| IPO Year | 2014 | 2011 |
| Metric | HRTG | CAPR |
|---|---|---|
| Price | $34.42 | $8.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $33.50 | ★ $44.63 |
| AVG Volume (30 Days) | 232.5K | ★ 9.3M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 214.43 | N/A |
| EPS | ★ 3.23 | N/A |
| Revenue | ★ $847,330,000.00 | N/A |
| Revenue This Year | $7.50 | N/A |
| Revenue Next Year | $6.74 | $3.31 |
| P/E Ratio | $10.54 | ★ N/A |
| Revenue Growth | ★ 3.71 | N/A |
| 52 Week Low | $20.48 | $2.96 |
| 52 Week High | $36.50 | $40.37 |
| Indicator | HRTG | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 59.15 | 43.03 |
| Support Level | $25.34 | $6.01 |
| Resistance Level | $36.06 | $11.00 |
| Average True Range (ATR) | 1.03 | 1.07 |
| MACD | -0.22 | 0.41 |
| Stochastic Oscillator | 43.11 | 45.89 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance across various states in the U.S. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. The company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, and South Carolina.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.